JP2018199733A5 - - Google Patents

Download PDF

Info

Publication number
JP2018199733A5
JP2018199733A5 JP2018182242A JP2018182242A JP2018199733A5 JP 2018199733 A5 JP2018199733 A5 JP 2018199733A5 JP 2018182242 A JP2018182242 A JP 2018182242A JP 2018182242 A JP2018182242 A JP 2018182242A JP 2018199733 A5 JP2018199733 A5 JP 2018199733A5
Authority
JP
Japan
Prior art keywords
collagenase
pharmaceutical composition
composition according
purified
purified collagenase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018182242A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018199733A (ja
JP6649449B2 (ja
Filing date
Publication date
Priority claimed from US11/703,269 external-priority patent/US20070224184A1/en
Application filed filed Critical
Publication of JP2018199733A publication Critical patent/JP2018199733A/ja
Publication of JP2018199733A5 publication Critical patent/JP2018199733A5/ja
Application granted granted Critical
Publication of JP6649449B2 publication Critical patent/JP6649449B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018182242A 2006-02-22 2018-09-27 セルライト処置用コラゲナーゼ Active JP6649449B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77569006P 2006-02-22 2006-02-22
US60/775,690 2006-02-22
US11/703,269 US20070224184A1 (en) 2006-02-22 2007-02-07 Method for treating cellulite
US11/703,269 2007-02-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016179732A Division JP6498167B2 (ja) 2006-02-22 2016-09-14 セルライト処置用コラゲナーゼ

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019200656A Division JP6853331B2 (ja) 2006-02-22 2019-11-05 セルライト処置用コラゲナーゼ

Publications (3)

Publication Number Publication Date
JP2018199733A JP2018199733A (ja) 2018-12-20
JP2018199733A5 true JP2018199733A5 (cg-RX-API-DMAC7.html) 2019-03-22
JP6649449B2 JP6649449B2 (ja) 2020-02-19

Family

ID=38325147

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2008556445A Active JP5775658B2 (ja) 2006-02-22 2007-02-22 セルライト処置用コラゲナーゼ
JP2015095704A Pending JP2015134840A (ja) 2006-02-22 2015-05-08 セルライト処置用コラゲナーゼ
JP2016179732A Active JP6498167B2 (ja) 2006-02-22 2016-09-14 セルライト処置用コラゲナーゼ
JP2018182242A Active JP6649449B2 (ja) 2006-02-22 2018-09-27 セルライト処置用コラゲナーゼ
JP2019200656A Active JP6853331B2 (ja) 2006-02-22 2019-11-05 セルライト処置用コラゲナーゼ

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2008556445A Active JP5775658B2 (ja) 2006-02-22 2007-02-22 セルライト処置用コラゲナーゼ
JP2015095704A Pending JP2015134840A (ja) 2006-02-22 2015-05-08 セルライト処置用コラゲナーゼ
JP2016179732A Active JP6498167B2 (ja) 2006-02-22 2016-09-14 セルライト処置用コラゲナーゼ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019200656A Active JP6853331B2 (ja) 2006-02-22 2019-11-05 セルライト処置用コラゲナーゼ

Country Status (19)

Country Link
US (4) US20070224184A1 (cg-RX-API-DMAC7.html)
EP (1) EP1991258B1 (cg-RX-API-DMAC7.html)
JP (5) JP5775658B2 (cg-RX-API-DMAC7.html)
KR (2) KR20120006063A (cg-RX-API-DMAC7.html)
AU (1) AU2007221225B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0708186A2 (cg-RX-API-DMAC7.html)
CA (1) CA2643171C (cg-RX-API-DMAC7.html)
DK (1) DK1991258T3 (cg-RX-API-DMAC7.html)
ES (1) ES2553184T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20151182T1 (cg-RX-API-DMAC7.html)
HU (1) HUE025918T2 (cg-RX-API-DMAC7.html)
IL (1) IL193639A (cg-RX-API-DMAC7.html)
MX (1) MX2008010767A (cg-RX-API-DMAC7.html)
NZ (1) NZ570642A (cg-RX-API-DMAC7.html)
PL (1) PL1991258T3 (cg-RX-API-DMAC7.html)
PT (1) PT1991258E (cg-RX-API-DMAC7.html)
RS (1) RS54372B1 (cg-RX-API-DMAC7.html)
SI (1) SI1991258T1 (cg-RX-API-DMAC7.html)
WO (1) WO2007100675A2 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958150B2 (en) 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
SI1846022T1 (sl) * 2005-01-21 2016-01-29 The Research Foundation Of State University Of New York Postopki za zdravljenje adhezivnega kapsulitisa
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
WO2008008468A2 (en) * 2006-07-14 2008-01-17 Duncan Diane I Compositions and methods for fat reduction
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
CA2754461A1 (en) * 2009-03-06 2010-09-10 Halozyme, Inc. Temperature sensitive mutants of matrix metalloprotease 1 and uses thereof
JP5284239B2 (ja) * 2009-10-07 2013-09-11 株式会社メタコ スクリーン装置
FR2966734B1 (fr) * 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
PT2768523T (pt) * 2011-10-21 2019-08-29 Endo Global Ventures Processo para tratar ou reduzir a efp
PT2802652T (pt) 2012-01-12 2019-09-10 Endo Global Ventures Enzimas de clostridium histolyticum
WO2014066622A2 (en) 2012-10-24 2014-05-01 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
US20150196625A9 (en) 2013-01-07 2015-07-16 Rudolph D. Paladini Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
US9744138B2 (en) 2013-03-15 2017-08-29 Biospecifics Technologies Corp. Treatment method and product for uterine fibroids using purified collagenase
US10117892B2 (en) 2013-08-29 2018-11-06 Allergan, Inc. Devices and methods for reducing the appearance of cellulite
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
DK3589204T3 (da) * 2017-03-01 2025-06-30 Endo Operations Ltd Apparat og fremgangsmåde til vurdering og behandling af cellulitis
AU2018244426B2 (en) 2017-03-28 2024-09-19 Endo Ventures Limited Improved method of producing collagenase
WO2020021332A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020021330A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020058755A1 (en) * 2018-09-18 2020-03-26 Endo Global Aesthetics Limited Compositions and methods for treating cellulite
KR20210113271A (ko) * 2019-01-06 2021-09-15 엔도 글로벌 에스테틱스 리미티드 콜라게나제 제형 및 이의 제조 방법
AU2020366008B2 (en) 2019-10-15 2025-08-28 Biospecifics Technologies Corp. Treatment of uterine fibroids using purified collagenase
EP4041288A4 (en) * 2019-11-26 2023-02-22 Standard of Care Corporation HYALURONIDASE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING CELLULITE
CN119677498A (zh) * 2022-05-10 2025-03-21 恩多全球美学有限公司 减少具有脂肪团的受试者中胶原酶介导的瘀伤的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338300A (en) * 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5332503A (en) * 1993-04-16 1994-07-26 Baxter International Inc. Process for purifying collagenase
CA2189646C (en) * 1994-06-24 1999-05-25 Francis E. Dwulet A purified mixture of collagenases and two other proteases obtained from clostridium histolyticum
US5589171A (en) * 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
CA2158822C (en) * 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
US6958150B2 (en) * 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US5830741A (en) * 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US6086872A (en) * 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
CA2317066A1 (en) * 1997-10-03 1999-04-15 Lavipharm Laboratories, Inc. A prolamine-plant polar lipid composition, its method of preparation and applications thereof
US6022539A (en) * 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
WO2001013865A1 (en) * 1999-08-20 2001-03-01 Howard Murad Pharmaceutical compositions and methods for reducing the appearance of cellulite
SI1846022T1 (sl) * 2005-01-21 2016-01-29 The Research Foundation Of State University Of New York Postopki za zdravljenje adhezivnega kapsulitisa
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
US20210169844A1 (en) * 2019-12-10 2021-06-10 Tulex Pharmaceuticals Inc. Compositions and methods for treating epilepsy, seizures and other conditions

Similar Documents

Publication Publication Date Title
JP2018199733A5 (cg-RX-API-DMAC7.html)
JP2016204396A5 (cg-RX-API-DMAC7.html)
HRP20151182T1 (hr) Kolagenaza za tretiranje celulita
Fu et al. Emerging role of immunity in cerebral small vessel disease
Robinson Medical therapy of inflammatory bowel disease for the 21st century
RU2018118651A (ru) Композиции и способы терапии, связанной с фекальной микробиотой
JP2023120246A5 (cg-RX-API-DMAC7.html)
CY1109425T1 (el) Φαρμακευτικες συνθεσεις για τη χορηγηση με ελεγχομενη αποδεσμευση βιολογικα δραστικων ενωσεων
JP2016515586A5 (cg-RX-API-DMAC7.html)
Ponticelli et al. Current and emerging treatments for idiopathic focal and segmental glomerulosclerosis in adults
JP2005522527A5 (cg-RX-API-DMAC7.html)
Nakao et al. Studies on erythropoietic action of angiotensin II
RU2019141383A (ru) Способы лечения цервикальной дистонии
MX2022016063A (es) Compuestos de oxazolidinona, composiciones de liposomas que comprenden compuestos de oxazolidinona y metodos de uso de los mismos.
Zhao et al. Combination of thalidomide and Clostridium butyricum relieves chemotherapy-induced nausea and vomiting via gut microbiota and vagus nerve activity modulation
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
Highsmith et al. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma
WO2005120542A3 (en) Methods of treating disease with random copolymers
ME02344B (me) Postupci lečenja adhezivnog kapsulitisa
JP2020536923A5 (cg-RX-API-DMAC7.html)
KR20240063969A (ko) 클리스트리디움 곤디 포자와 펨브롤리주맙의 연합의 응용
IL273909B1 (en) Treatment of cd20-positive b-cell lymphoma with obituzumab
Ignatius et al. Efficacies of omadacycline+ amikacin+ imipenem and an all-oral regimen omadacycline+ clofazimine+ linezolid in a mouse model of M. abscessus lung disease
Kim et al. Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer
US20220016147A1 (en) Application of chidamide in combination with r-chop, and drug combination